Sarcopenia in rheumatoid Arthritis

Conditions

M05 M06

Roswitha Dietzel, Sabine Wiegmann, Diana Borucki, Christian Detzer, Kim Nikola Zeiner et al. (9 authors)

RMD Open2022-09-0136 citations

10.1136/rmdopen-2022-002600

Balance and prospective falls in patients with rheumatoid arthritis.

Wiegmann S, Armbrecht G, Borucki D, Buehring B, Buttgereit F, Detzer C, Schaumburg D, Zeiner KN, Dietzel R.

2022-06-074 citations

10.1186/s12891-022-05489-1

Association between sarcopenia, physical performance and falls in patients with rheumatoid arthritis: a 1-year prospective study.

Wiegmann S, Armbrecht G, Borucki D, Buehring B, Buttgereit F, Detzer C, Schaumburg D, Zeiner KN, Dietzel R.

2021-10-1812 citations

10.1186/s12891-021-04605-x

Interventions

Group 1: Patients with rheumatoid arthritis (with and without sarcopenia) will be measured in a single visit: Muscle mass with dual-X-ray absorptiometry

muscle size and muscle density at the tibia with peripheral quantitative computed tomography

neuromuscular assessment of muscle force, muscle power and balance on a force plate system

grip strength

serum parameters

standardised questionnaires: health assessment questionnaire, quality of life SF-36, self reported balance (ABC scale), physical acivity (IPAQ_short)

fatigue questionnaire (Bristol RA Fatigue - numerical rating scales BRAF-NRS)

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Diagnosis of RA (2/3 of the subjects with low disease activity based on the Disease Activity Score (DAS-28) =3.2; Ambulant (also with walking aid). Written informed consent.

Exclusion criteria

Exclusion criteria: Any injury in the last 3 months affecting the musculoskeletal system. Any acute disease or worsening of a chronic condition affecting the musculoskeletal system. Participation in another clinical study. Pregnancy.

Design outcomes

Primary

Measure	Time frame
The aim of the study is to determine the prevalence of sarcopenia in rheumatoid arthritis using different definitions of sarcopenia (European Working Group on Sarcopenia in Older People EWGSOP, National Institutes of Health FNIH, ESPEN Consensus Statement)	—

Secondary

Measure	Time frame
Additional aims are: Comparison of RA patients with and without sarcopenia concerning muscle parameters, physical activity, quality of life and blood parameter. Association between sarcopenia in RA and influencing factors such as disease activity and duration, therapy with glucocorticoids, physical activity or sun light exposition. Differences in muscle mass, muscle function, physical activity and blood parameters between RA patients and healthy controls.	—

Measure

Time frame

Additional aims are: Comparison of RA patients with and without sarcopenia concerning muscle parameters, physical activity, quality of life and blood parameter. Association between sarcopenia in RA and influencing factors such as disease activity and duration, therapy with glucocorticoids, physical activity or sun light exposition. Differences in muscle mass, muscle function, physical activity and blood parameters between RA patients and healthy controls.

—

Countries

Germany

Contacts

Public ContactRoswitha Dietzel

Zentrum für Muskel- und Knochenforschung; Charité- Campus Benjamin Franklin

roswitha.dietzel@charite.de030-8445-4539

Outcome results

None listed